
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
This condition may be easily overlooked because of its insidious nature. Combining history, physical exam, and hematologic tests allows you to distinguish it from other forms of red cell aplasia.






